Shenzhen Salubris Pharmaceuticals Co., Ltd.
尊龙凯时-人生就是搏!
join us
CN
Home page
About Us
Profile
Affiliates/Subsidiaries
Development History
Quality Management
Contact Us
Legal Statement
Adverse Reaction Report
Science and Technology
R&D platform
R&D pipeline
Therapeutic Field
International Business
APIs
Finished Products
Medical device
Download product list
Contact
News Center
News & Trends
Public information
News & Trends
02
2022-08
The updated progress of clinical trial for SAL0114
27
2022-07
SAL007 for the treatment of chronic heart failure approved by NMPA for clinical trial
28
2022-06
Updated progress of S086 tablets in Phase 3 clinical trial for the treatment of chronic heart failure
28
2022-06
Updated progress of Fotagliptin benzoate tablets in Phase 3 clinical trial for the treatment of diabetes
21
2022-06
Salubris’ LAMax LAAC® left atrial appendage closure system receives NMPA approval
27
2022-05
Updated progress of Allisartan Isoproxil and Indapamide sustained-release tablets in Phase 3 trial for the treatment of essential hypertension
目前在第
5
页,
共有
9
页,
共有
50
条记录
第一页
上一页
3
4
5
6
7
下一页
最后一页
跳转到
页